Advanced Solid Tumor Clinical Trials & Research at Providence Medical Group

Advanced solid tumors represent a significant challenge in oncology, characterized by their resistance to conventional therapies and their potential to metastasize, leading to poor prognosis for patients. These tumors are often defined by their stage, typically stage III or IV, indicating local invasion or distant spread. Common types include advanced stages of breast, lung, colorectal, and pancreatic cancers, among others.

Providence Medical Group is currently enrolling patients for the following advanced solid tumor clinical trials:

Study to Assess the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors

Treatment agent: ART0380 + Irinotecan
Physician: Ian Anderson, MD
Study Coordinator: Melissa Ulrich // melissa.ulrich@providence.org // 707-521-3830
Study Resources: Study Details | A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors | ClinicalTrials.gov
Sponsor: Artios Pharma Ltd.
Location: Providence Cancer Center, Santa Rosa, CA

EMD Serono MS201924-0020 (DDriver solid tumors 320)- Metastatic or Locally Advanced Unresectable solid tumors. Prostate/Endometrial Cancer

Treatment agent: (Open label): M1774, M4076 (orals) + Avelumab (IV)
Physician: Ian Anderson, MD
Study Coordinator: Teresa Lund // teresa.lund@stjoe.org // 707-521-3830
Study Resources: Abstract CT063: Phase Ib trial of ATR inhibitor (ATRi) tuvusertib + ATM inhibitor (ATMi) lartesertib (M4076) in patients (pts) with advanced solid tumors | Cancer Research | American Association for Cancer Research (aacrjournals.org)
Sponsor: IQVIA
Location: Providence Cancer Center, Santa Rosa, CA